Atlas Venture has entered into Corporate Strategic Partnership (CSP) agreements with both Amgen, through its venture capital fund, Amgen Ventures, and Novartis. The CSP agreements are in conjunction with the closing of Atlas IX in which Amgen Ventures and Novartis are new limited partners.
Berlin's renowned Charite hospital said Monday it plans to investigate allegations that patients in communist East Germany were used as unwitting guinea pigs in medical trials for Western drug companies. Claims that the dictatorship allowed tests that would have been considered unethical or even illegal in the West were first made shortly after German reunification in 1990, but no wrongdoing was found at the time.
Oxford BioMedica, the leading gene-based biopharmaceutical company, announces that it has signed an agreement with Novartis to manufacture clinical grade material utilising Oxford BioMedica’s LentiVector® gene delivery technology. Oxford BioMedica will also provide certain process development services and expects to receive between £2.5 million and £4 million from Novartis over the next 12 months.
Concerned about the skyrocketing cost of cancer treatment, cancer specialists are demanding that drug companies roll back their prices on cancer treatments. In a scathing report doctors are saying that the costs of cancer drugs are unsustainable and harming patients.
The U.S. government sued Novartis Pharmaceuticals Corp. again on Friday, saying it paid kickbacks for a decade to doctors to steer patients toward its drugs, sometimes disguising fishing trips off the Florida coast and trips to Hooters restaurants as speaking engagements for the doctors.
Novartis plans to trim production and cut about 300 jobs from its Lincoln, Neb. payroll. The Swiss pharmaceutical company said Wednesday that the job cuts will occur over the next two years, leaving about 450 workers to concentrate on making three products: Excedrin, Theraflu and a veterinary medication, Sentinel.
Swiss pharmaceutical company Novartis AG has reported a 6.7 percent increase in profit for the first quarter, boosted by new products and emerging markets. Novartis says its net profit rose to $2.42 billion from $2.27 billion in the same period last year. The Basel-based company said in a...
The India Supreme Court's rejection of a patent for an improved version of a costly cancer drug by Novartis AG could have big implications for the world's largest drugmakers. The ruling, which was handed down on Monday, signals the latest shift in the world of drug development in emerging markets...
India's Supreme Court on Monday rejected drug maker Novartis AG's right to patent a new version of a cancer drug in a landmark decision that healthcare activists say ensures the poor will get continued access to cheap, generic versions of lifesaving medicines. Novartis had argued that it needed...
Novartis announced that the FDA approved TOBI Podhaler, an inhaled powder formulation of tobramycin, for the management of cystic fibrosis (CF) patients with Pseudomonas aeruginosa bacteria in the lungs. Edward Cox noted that the "product is the first dry powder antibacterial drug delivered with a handheld dry powder inhaler."
Novartis AG said Friday that its experimental cancer drug LDK378 was designated as a breakthrough therapy by the Food and Drug Administration. The Swiss drugmaker is studying LDK378 as a treatment for a rare type of metastatic non-small cell lung cancer. It is intended for patients whose cancer...
More than two dozen of the world's largest pharmaceutical companies have agreed to provide funding and other support to Interpol's battle against counterfeit prescription drugs, the international police agency said Tuesday. Interpol's newly created Pharmaceutical Crime Program aims to help health...
Orexo AB today announced that Novartis AG has sent a notice of termination of the license agreement dated August 27, 2009. The OX17 program was aimed for the treatment of gastroesophageal reflux disease (GERD) and is still in early clinical phase.
The outgoing chairman of Swiss drug maker Novartis AG has agreed to cancel a much-criticized deal under which he stood to earn up to 72 million francs ($78 million) for not advising competitors over the coming years. Daniel Vasella, the company's long-time chairman and former chief executive, is...
The ALS Therapy Development Institute (ALS TDI) announced today that it has received FDA approval to conduct a clinical trial of TDI-132 (aka: fingolimod, Gilenya) in ALS. Fingolimod is currently being marketed by Novartis AG as Gilenya as a treatment for some forms of multiple sclerosis.
Health Canada is advising Canadians that Novartis Consumer Health Canada Inc. is conducting a voluntary recall of 17 products (see chart below) as the child resistant mechanism of the bottle cap can fail. As a result, children may be able to open the bottle and ingest the product. The ingredients of the affected products may be harmful to children.
The Facility of the Year Awards Judging Panel has named six Category Award Winners in the 2013 Facility of the Year Awards (FOYA) program. The winning projects for 2013 were selected from 27 well-qualified entries.
The European Medicines Agency has been formally notified by Novartis Europharm Ltd of its decision to withdraw its application for a centralized marketing authorization for the medicine Ruvise.
Novartis has announced that the FDA has approved Signifor (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.
The Food and Drug Administration says it has approved the first seasonal flu vaccine made using animal cell technology, rather than the half-century-old egg method.
Europe's top drug regulator has recommended approval for the first vaccine against meningitis B, made by Novartis AG.
The National Institute for Health and Clinical Excellence published draft guidance Friday recommending against NHS reimbursement of Novartis' Xolair (omalizumab) for treating severe, persistent allergic asthma in adults, overturning an earlier ruling.
Novartis Drug Signifor Recommended by FDA Advisory Committee for Approval to Treat Patients with Cushing's DiseaseNovember 8, 2012 3:26 am | News | Comments
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted unanimously in support of the use of Signifor (pasireotide) for the treatment of patients with Cushing's disease who require medical therapeutic intervention.
A cancer treatment from Novartis received approval to be sold in Europe as a treatment for some patients with non-cancerous kidney tumors from a rare genetic disorder.
A senior executive with the pharmaceutical giant Novartis says the company is working around the clock to provide countries with the information they need to release flu vaccines currently being withheld from distribution.